Bob M. Moore II, Ph.D.

Bob M. Moore II, Ph.D.

Professor


Department of Pharmaceutical Sciences


The University of Tennessee Health Science Center
874 Union Avenue, Room 327D
Memphis, TN 38163
Tel: (901) 448-6085
Fax: (508) 448-6828
Email: Bob M. Moore



Education

  • B.S. in Chemistry, Indiana State University, 1983
  • M.S. in Chemistry, Indiana State University, 1989
  • Ph.D. (Medicinal Chemistry), University of Kansas, 1995

Research Interests

Research in Dr. Moore's lab integrates synthetic organic chemistry, computational chemistry and biological assays aimed at developing new chemotherapeutic entities. The current areas of research include:

  1. Development of cannabinoid receptor (CB1 and CB2) agonist and antagonist.
  2. Development of novel therapies for combat causality care with emphasis on hemorrhagic shock and hemostasis.
  3. Development of GPRC directed anti-neoplastic agents.
  4. Combination drug therapies for the treatment of sepsis, stroke and ischemic brain conditions.

Representative Publications

  • Presley CS, Abidi AH, Moore BM 2nd. Cannabinoid receptor 1 ligands revisited: Pharmacological assessment in the ACTOne system. Anal Biochem. 2016 Jan 7;498:8-28. doi: 10.1016/j.ab.2015.12.019. [Epub ahead of print] PubMed PMID: 26772161.
  • Harrold I, Carbonneau S, Moore BM, Nguyen G, Anderson NM, Saini AS, Kanki JP, Jette CA, Feng H. Efficient transgenesis mediated by pigmentation rescue in zebrafish. Biotechniques. 2016 Jan 1;60(1):13-20. doi: 10.2144/000114368. eCollection 2016. PubMed PMID: 26757807.
  • Presley CS, Mustafa SM, Abidi AH, Moore BM 2nd. Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist. Bioorg Med Chem. 2015 Sep 1;23(17):5390-401. doi: 10.1016/j.bmc.2015.07.057. Epub 2015 Jul 29. PubMed PMID: 26275680.
  • Presley C, Abidi A, Suryawanshi S, Mustafa S, Meibohm B, Moore BM. Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. Pharmacol Res Perspect. 2015 Aug;3(4):e00159. doi: 10.1002/prp2.159. Epub 2015 Jul 6. PubMed PMID: 26196013; PubMed Central PMCID: PMC4506688.
  • Brady SL, Mirro AE, Moore BM, Kaufman RA. How to Appropriately Calculate Effective Dose for CT Using Either Size-Specific Dose Estimates or Dose-Length Product. AJR Am J Roentgenol. 2015 May;204(5):953-8. doi: 10.2214/AJR.14.13317. Epub 2015 Mar 2. PubMed PMID: 25729893.
  • Reiner A, Heldt SA, Presley CS, Guley NH, Elberger AJ, Deng Y, D'Surney L, Rogers JT, Ferrell J, Bu W, Del Mar N, Honig MG, Gurley SN, Moore BM 2nd. Motor, visual and emotional deficits in mice after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse agonist SMM-189. Int J Mol Sci. 2014 Dec 31;16(1):758-87. doi: 10.3390/ijms16010758. PubMed PMID: 25561230; PubMed Central PMCID: PMC4307274.

View more references (pubmed link)